Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance)

Journal of Clinical Oncology jco.ascopubs.org

1. Published online before print August 17, 2015, doi: 10.1200/JCO.2015.61.5062 JCO August 17, 2015 JCO.2015.61.5062

© 2015 by American Society of Clinical Oncology

1. Brendan J. Guercio,
2. Kaori Sato,
3. Donna Niedzwiecki,
4. Xing Ye,
5. Leonard B. Saltz,
6. Robert J. Mayer,
7. Rex B. Mowat,
8. Renaud Whittom,
9. Alexander Hantel,
10. Al Benson,
11. Daniel Atienza,
12. Michael Messino,
13. Hedy Kindler,
14. Alan Venook,
15. Frank B. Hu,
16. Shuji Ogino,
17. Kana Wu,
18. Walter C. Willett,
19. Edward L. Giovannucci,
20. Jeffrey A. Meyerhardt and
21. Charles S. Fuchs†

+ Author Affiliations
1. Brendan J. Guercio, Shuji Ogino, and Edward L. Giovannucci, Harvard Medical School; Kaori Sato, Robert J. Mayer, Shuji Ogino, Jeffrey A. Meyerhardt, and Charles S. Fuchs, Dana-Farber Cancer Institute; Frank B. Hu, Shuji Ogino, Kana Wu, Walter C. Willett, and Edward L. Giovannucci, Harvard T.H. Chan School of Public Health; Shuji Ogino and Edward L. Giovannucci, Brigham and Women's Hospital, Boston, MA; Leonard B. Saltz, Memorial Sloan Kettering Cancer Center, New York, NY; Rex B. Mowat, Toledo Community Hospital Oncology Program, Toledo, OH; Renaud Whittom, Hôpital du Sacré-Cœur de Montréal, Montreal, Quebec, Canada; Alexander Hantel, Loyola University Stritch School of Medicine, Naperville; Al Benson, Northwestern University; Hedy Kindler, University of Chicago, Chicago, IL; Daniel Atienza, Virginia Oncology Associates, Norfolk, VA; Donna Niedzwiecki and Xing Ye, Duke University Medical Center, Durham; Michael Messino, Southeast Cancer Control Consortium, Mission Hospitals, Asheville, NC; and Alan Venook, University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA.

1. Corresponding author: Charles S. Fuchs, MD, MPH, Dana-Farber Cancer Institute, 450 Brookline Ave, Room D1220, Boston, MA 02215; e-mail: charles_fuchs@dfci.harvard.edu.

1. Both J.A.M. and C.S.F. contributed equally to this work.

Abstract

Purpose Observational studies have demonstrated increased colon cancer recurrence in states of relative hyperinsulinemia, including sedentary lifestyle, obesity, and increased dietary glycemic load. Greater coffee consumption has been associated with decreased risk of type 2 diabetes and increased insulin sensitivity. The effect of coffee on colon cancer recurrence and survival is unknown.

Patients and Methods During and 6 months after adjuvant chemotherapy, 953 patients with stage III colon cancer prospectively reported dietary intake of caffeinated coffee, decaffeinated coffee, and nonherbal tea, as well as 128 other items. We examined the influence of coffee, nonherbal tea, and caffeine on cancer recurrence and mortality using Cox proportional hazards regression.

Results Patients consuming 4 cups/d or more of total coffee experienced an adjusted hazard ratio (HR) for colon cancer recurrence or mortality of 0.58 (95% CI, 0.34 to 0.99), compared with never drinkers (P_{trend} = .002). Patients consuming 4 cups/d or more of caffeinated coffee experienced significantly reduced cancer recurrence or mortality risk compared with abstainers (HR, 0.48; 95% CI, 0.25 to 0.91; P_{trend} = .002), and increasing caffeine intake also conferred a significant reduction in cancer recurrence or mortality (HR, 0.66 across extreme quintiles; 95% CI, 0.47 to 0.93; P_{trend} = .006). Nonherbal tea and decaffeinated coffee were not associated with patient outcome. The association of total coffee intake with improved outcomes seemed consistent across other predictors of cancer recurrence and mortality.

Conclusion Higher coffee intake may be associated with significantly reduced cancer recurrence and death in patients with stage III colon cancer.

Footnotes

- Supported by the National Cancer Institute of the National Institutes of Health Grants No. U10CA180821 and U10CA180882 to the Alliance for Clinical Trials in Oncology, CA31946 and CA33601 to the legacy Cancer and Leukemia Group B, and CA180820 to the Eastern Cooperative Oncology Group–American College of Radiology Imaging Network. Additional support was provided by Grants No. CA32291, CA77651, CA45808, and CA60138 from National Institutes of Health, by a grant from the Perry S. Levy Fund for Gastrointestinal Cancer Research, and by Pharmacia & Upjohn Company, now Pfizer Oncology. C.S.F. and J.A.M. are supported in part by the National Cancer Institute (Grants No. R01-CA118553, R01-CA149222, R01-CA169141, and P50-CA127003).
- Terms in blue are defined in the glossary, found at the end of this article and online at www.jco.org.

- The sponsors did not participate in the design or conduct of the study; collection, management, analysis, or interpretation of the data; or preparation, review, or approval of the manuscript.

- Authors’ disclosures of potential conflicts of interest are found in the article online at www.jco.org. Author contributions are found at the end of this article.

**Glossary Terms**

Cox proportional hazards:
   
   See *Cox proportional hazards regression model*.

C-peptide:
   
   A protein fragment produced during the enzymatic cleavage of proinsulin to create insulin. It is secreted by pancreatic β-cells at equimolar concentrations to insulin but has a half-life in the circulation of two to five times longer. Because its greater stability in the peripheral circulation, C-peptide has been measured in research studies as a marker of pancreatic β-cell secretory activity.

Western pattern diet:
   
   Western pattern diet is characterized by high intakes of red and processed meats, fat, refined grains, and dessert.